Abstract LB197: A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer

克拉斯 医学 埃利斯波特 肽疫苗 T细胞 佐剂 免疫学 CD8型 癌症研究 外周血单个核细胞 癌症 免疫疗法 癌症疫苗 接种疫苗 免疫系统 内科学 抗原 表位 生物 结直肠癌 体外 生物化学
作者
Amanda L. Huff,Saurav Daniel Haldar,Emily F. Davis-Marcisak,Thatcher Ross Heumann,Gabriella Longway,Alexei Hernandez,Maximilian F. Konig,Brian J. Mog,Ludmila Danilova,Luciane Tsukamoto Kagohara,Julie M. Nauroth,Amy Morck Thomas,Elana Judith Fertig,Won Jin Ho,Elizabeth M. Jaffee,Nilo Azad,Neeha Zaidi
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (8_Supplement): LB197-LB197 被引量:8
标识
DOI:10.1158/1538-7445.am2023-lb197
摘要

Abstract Background: Oncogenic mutations in KRAS are expressed in up to 90% of pancreatic ductal adenocarcinomas (PDAC). Vaccination against mutant KRAS (mKRAS) is thus a promising approach as an off-the-shelf immunotherapeutic treatment for PDAC. We developed a mKRAS peptide vaccine targeting 6 common KRAS mutations (G12V, G12A, G12C, G12R, G12D, or G13D (NCT04117087). We evaluated the mKRAS specific T cell response induced by vaccination in combination with immune checkpoint inhibitors (ICIs) in patients with resected PDAC. Materials and Methods: This is an ongoing pilot study of a pooled mKRAS long peptide vaccine in combination with ICIs in patients with resected PDAC and mutations in one of 6 KRAS mutations in our vaccine. Patients with no evidence of disease on imaging within 6 months of completion of adjuvant chemotherapy were vaccinated with the mKRAS vaccine (0.3mg/peptide and 0.5mg poly-ICLC (Hiltonol: Oncovir)) weekly for 4 doses followed by booster vaccines every 8 weeks. Patients also received ipilimumab (1mg/kg, every 6 weeks for 2 doses) and nivolumab (3mg/kg, every 3 weeks in the priming phase) followed by nivolumab (480mg, flat dose in boost phase). To evaluate the expansion of mKRAS-specific T cells in the periphery, pre- and post-vaccination peripheral blood mononuclear cells (PBMCs) were restimulated with control or individual mKRAS peptides and assessed for IFNγ release by ELISPOT. To further phenotype the responding CD4 and CD8 T cell compartments, peptide-restimulated PBMCs were evaluated for T cell activation, proliferation, memory and exhaustion marker expression by CyTOF. Paired single-cell RNA and TCR sequencing are being performed to isolate mKRAS-specific TCRs and their corresponding transcriptional profiles. These TCRs are being functionally validated in vitro using CRISPR-Cas12a-based genome knock-in of human T cells. Results: At the time of data cut off (1/12/2023) 8/11 patients enrolled had a positive mKRAS-specific T cell response in post-vaccine sample timepoints defined by a >5 fold increase in IFNγ producing T cells after peptide restimulation. CyTOF analysis of peptide-restimulated PBMCs demonstrated expansion of polyfunctional (IFNγ+IL2+TNFα+) mKRAS-specific CD4 and CD8 T cells with both central and effector memory phenotypes after vaccination. mKRAS-specific CD4 T cells were induced at a greater proportion. Our single-cell analysis has identified and validated a novel CD4+ TCR that recognizes KRAS G12V in the context of HLA-DRB1*07:01. Conclusions: This study thus far indicates the induction of de novo, high quality mKRAS-specific T cells in the periphery post-vaccine. Ongoing studies will define TCR diversity and clonality of mKRAS-specific T cells to each mKRAS epitope. Overall, our data will be used to identify peripheral T cell-based biomarkers that may be able to predict response to mKRAS-targeted immunotherapy. Citation Format: Amanda L. Huff, Saurav D. Haldar, Emily Davis-Marcisak, Thatcher Heumann, Gabriella Longway, Alexei Hernandez, Maximillian F. Konig, Brian Mog, Ludmila Danilova, Luciane Kagohara, Julie M. Nauroth, Amy M. Thomas, Elana J. Fertig, Won Jin Ho, Elizabeth M. Jaffee, Nilo Azad, Neeha Zaidi. A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB197.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CO_Pro完成签到,获得积分10
刚刚
爆米花的应助被corleeang采纳,获得10
刚刚
Jasper的应助被三笠采纳,获得10
1秒前
1秒前
1秒前
kkk完成签到,获得积分10
1秒前
1秒前
科研通AI6.3的应助被旺仔仔采纳,获得10
2秒前
小蘑菇的应助被Leo采纳,获得10
2秒前
you完成签到,获得积分10
2秒前
2秒前
搜集达人的应助被平生采纳,获得10
2秒前
余忆完成签到,获得积分20
2秒前
2秒前
朴实寻双发布了新的文献求助30
2秒前
zjz1的应助被yi采纳,获得10
2秒前
MoonByMoon完成签到,获得积分10
3秒前
123关闭了123的文献求助
3秒前
3秒前
大王完成签到,获得积分20
3秒前
3秒前
xianggua完成签到,获得积分10
4秒前
天天快乐的应助被Ma采纳,获得10
4秒前
4秒前
4秒前
赘婿的应助被精明的新蕾采纳,获得10
5秒前
AGNOY发布了新的文献求助10
5秒前
5秒前
qin202569发布了新的文献求助10
5秒前
星1993发布了新的文献求助10
5秒前
小时发布了新的文献求助10
5秒前
rongjian完成签到 ,获得积分10
6秒前
温暖的书竹完成签到 ,获得积分10
6秒前
余忆发布了新的文献求助10
7秒前
虾仁不wink完成签到,获得积分10
7秒前
NexusExplorer的应助被霸气安筠采纳,获得10
7秒前
SciGPT的应助被Lily采纳,获得10
8秒前
酷波er的应助被李小轩采纳,获得10
8秒前
斯文败类的应助被黄俊采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124